Conclusions
A streamlined procedure is now in place in the EU to facilitate a consistent approach for the assessment of the environmental risks of medicines containing GMOs. Different countries have different approaches to this issue, but the risks, and potential harms to the environment and population at large are weighted in each application.
Following available guidance is essential to avoid questions and delays at approval time and help the preparation of the environmental risk assessment necessary in all marketing applications.
With these initiatives regulators are answering the calls to facilitate research and assessment of the environmental risk aspects of medicines containing GMOs in Europe.